合成生物概念股浙江震元终止定增计划 将以自有自筹资金保障募投项目推进

Core Viewpoint - Zhejiang Zhenyuan has decided to terminate its plan for a private placement of shares originally intended to raise 495 million yuan due to the current capital market environment and the company's overall development strategy [1][4]. Group 1: Fundraising and Project Details - The company initially aimed to raise 495 million yuan to focus on core pharmaceutical industrial projects, including the raw material drug aggregation enhancement project and the Shangyu industrialization base project [2]. - The raw material drug aggregation enhancement project has a total investment of 481 million yuan, with 195 million yuan planned to be raised from the issuance. It is designed to have an annual production capacity of 436 tons and is expected to generate annual sales revenue of 565 million yuan and a net profit of 124 million yuan upon full production [2][3]. - The Shangyu industrialization base project has a total investment of 587 million yuan, with 300 million yuan planned to be raised. It aims to produce 2,400 tons of histidine and other products, with expected annual sales revenue of 624 million yuan and a net profit of 179 million yuan upon completion [3]. Group 2: Project Progress and Financial Status - Both projects are currently under construction and have not been affected by the termination of the share issuance. The raw material drug aggregation enhancement project has a construction progress of 40%, while the Shangyu industrialization base project has reached 95% completion [4][5]. - As of June 30, the company reported a cash balance of 513 million yuan, indicating sufficient liquidity despite a slight decrease from the end of 2024. The overall debt level remains manageable, with short-term borrowings of 20.08 million yuan and long-term borrowings of 169 million yuan [4].